A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
NCT Number: NCT06541652
Acronym: FFCD-2205
Status: RECRUITING
Study Type: OBSERVATIONAL
Conditions: Hepatocholangiocarcinoma|Fibrolamellar Carcinoma|Hepatic Epithelioid Hemangioendothelioma|Hepatoblastoma|Hepatic Neuroendocrine Carcinoma|Hepatic Carcinosarcomas|Hepatic Cystadenoma|Hepatic Leiomyosarcomas|Hepatic Angiosarcomas|Cholangiocarcinoma
Sponsor: Federation Francophone de Cancerologie Digestive
Collaborators: Société Nationale Française de Gastroentérologie
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 150
Study Design: Observational Model: |Time Perspective: p
Start Date: 2024-03-26
Completion Date: 2031-02
Locations: CHU Amiens picardie, Amiens, 80054, France|Chu Angers, Angers, 49933, France|Ch - Centresimone Veil de Beauvais, Beauvais, 60021, France|Ch Bethune Beuvry, Bethune, 62408, France|Avicenne, Bobigny, 93000, France|Chu de Clichy Hopital Beaujon, Clichy, 92110, France|Centre Hospitalier Universitaire Henri Mondor, Creteil, 94010, France|CHU, Dijon, 21079, France|Chu Grenobles Alpes, La Tronche, 38700, France|Centre Hospital Universitaire de lille, Lille, 59000, France|Longjumeau Ch, Longjumeau, France|Ch Edouard Herriot, Lyon, 69002, France|Centre Léon Berard, Lyon, 69008, France|La Clinique de La Sauvegarde, Lyon, 69009, France|Hopital Saint Joseph, Marseille, 13285, France|Chu de La Timone, Marseille, 13385, France|CHR - Metz Thionville Hopital de Mercy, Metz, 57085, France|Chu de Paris Saint Antoine, Paris, 75571, France|AP - HP - Pitié Salpêtrière, Paris, 75651, France|PAU CH, Pau, 64000, France|Centre Hospitalier de Perpignan, Perpignan, 66046, France|Hopital Haut Leveque, Pessac, 33604, France|Chu de Poitiers, Poitiers, 86021, France|CH - Annecy Genevois, Pringy, 74374, France|Chu Robert Debre, Reims, 51000, France|CAC - Eugène Marquis, Rennes, 35042, France|Ico Site Rene Gauducheau, Saint-Herblain, 44805, France|Groupe Hospitalier Rance Emeraude, Saint-Malo, 35403, France|Chru de Tours, Tours, 37044, France

Summary:
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Primary Outcome Measures: Description of the clinical, histological and radiological characteristics of various rare primary liver cancers, Description of the clinical, histological and radiological characteristics of various rare primary liver cancers, up to 5 years from the date of diagnosis
Secondary Outcome Measures: Recurrence-free survival (for non-metastatic patients), Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news, up to 5 years from diagnosis|Progression-free survival (for metastatic patients), Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news., up to 5 years from diagnosis|Overall survival, Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news., up to 5 years from diagnosis